The Mahidol/TCELS CD19 CAR constructs resulted from the research works developed by Prof. Dr. Suradej Hongeng and his team, with supports from Ramathibodi hospital, Mahidol University and Thailand Center of Excellence for Life Sciences. The phase I clinical trial for evaluating toxicity and efficacy is expected to begin in early 2022. The CD19 CAR T-cells using in the clinical trial will be manufactured in Genepeutic Bio production facility.
GENEPEUTIC BIO CO.,LTD
Genepeutic Bio was founded in 2020 to deliver the next wave of personalized cell and gene therapy for patients in Asia, initiating with Chimeric antigen receptor (CAR) T-cells.